We believe in the long-term potential at the best companies, however, so we purchased Celera. Understanding these companies is a different matter than understanding a young drug-producing biotech. It's a great place to start. That word, proteomics, may be one of the most important words in relation to drug discovery over the next 50 years. In our recent Rule Breaker biotech chat , David Gardner said he believed proteomics would create more value than many other biotech fields.
Proteomics is the study of proteins for drug development.
That grossly simplifies it, however. Many companies are involved in proteomics. It is still early, but some investors suggest that proteomics will become a more important word than genomics. However you invest in biotechnology or bioinformatics, take your time and understand why you're buying whatever you buy. Enjoy your learning process in this fascinating field, and enjoy discussing it with others on biotech company boards.